SECUKINUMAB

Search structure

Action	Mechanism of Action	Reference
INHIBITOR	Interleukin 17A inhibitor

Mesh Heading	Maximum Phase	Mesh ID	Reference
Tendinopathy	3	D052256	ClinicalTrials
Arthritis, Rheumatoid	3	D001172	ClinicalTrials
Behcet Syndrome	3	D001528	ClinicalTrials
Uveitis	3	D014605	ClinicalTrials
Hidradenitis Suppurativa	3	D017497	ClinicalTrials
Polymyalgia Rheumatica	3	D011111	ClinicalTrials
Giant Cell Arteritis	3	D013700	ClinicalTrials
Lupus Nephritis	3	D008181	ClinicalTrials
Graves Ophthalmopathy	3	D049970	ClinicalTrials
Osteoarthritis	3	D010003	ClinicalTrials
Crohn Disease	2	D003424	ClinicalTrials
Inflammatory Bowel Diseases	2	D015212	ClinicalTrials
Necrobiosis Lipoidica	2	D009335	ClinicalTrials
Multiple Sclerosis	2	D009103	ClinicalTrials
Multiple Sclerosis, Relapsing-Remitting	2	D020529	ClinicalTrials
Diabetes Mellitus, Type 1	2	D003922	ClinicalTrials
Severe Acute Respiratory Syndrome	2	D045169	ClinicalTrials
Lupus Erythematosus, Discoid	2	D008179	ClinicalTrials
Alopecia Areata	2	D000506	ClinicalTrials
Lichen Planus	2	D008010	ClinicalTrials
Pyoderma	2	D011711	ClinicalTrials
Dermatitis, Atopic	2	D003876	ClinicalTrials
Asthma	2	D001249	ClinicalTrials
Dry Eye Syndromes	2	D015352	ClinicalTrials
Pityriasis Rubra Pilaris	1	D010916	ClinicalTrials
Rosacea	1	D012393	ClinicalTrials

System Organ Classification (SOC)

	Relative Frequency (%)
General disorders and administration site conditions	15.92
Skin and subcutaneous tissue disorders	12.6
Musculoskeletal and connective tissue disorders	9.19
Infections and infestations	8.81
Respiratory, thoracic and mediastinal disorders	8.58
Injury, poisoning and procedural complications	6.77
Gastrointestinal disorders	6.54
Immune system disorders	5.92
Nervous system disorders	5.59
Vascular disorders	3.32
Investigations	3.17
Psychiatric disorders	2.87
Cardiac disorders	2.5

CONTENTS


Active Pharmaceutical Ingredients (APIs) Scaffolds	Exact Similarity SubStructure	Threshold (%) >= 70